Advisory Board

He is board certified by the American Board of Internal Medicine in cardiovascular disease and interventional cardiology.  Dr. Gurley conceived the Inside-Out® concept and is named inventor of related patents.  Dr. Gurley is Professor of Medicine at the University of Kentucky HealthCare and Director, Structural Heart Program, of the Gill Heart & Vascular Institute at the University of Kentucky, Lexington, KY.

Dr. Bietz is a Vascular Surgeon in San Antonio and has been in practice for 9 years. He completed a residency at University of Kentucky. He currently practices at Peripheral Vascular Associates and is affiliated with Metropolitan Methodist Hospital in San Antonio, Texas.

Throughout her career, she has focused on the entire spectrum of commercialization needs: from upstream market development strategy to downstream product launch execution.

Katie founded SPRIG in 2008 in Silicon Valley in response to the emerging needs of early-stage medical technology start-ups to navigate company development with limited resources and strict financial constraints. Since SPRIG’s inception, Katie and her team have produced clear, measurable results for an exciting roster of clients.  The team has experience across a broad range of therapeutic spaces and offers a variety of services including business and clinical development, marketing and reimbursement strategies.

Prior to founding SPRIG, Katie had a successful career with Guidant Corporation (acquired) and Kensey Nash Corporation (acquired) launching novel technologies. Katie holds an MBA from Northwestern University’s Kellogg Graduate School of Management where she was awarded the Health Industry Management Scholarship. Katie is also a Kellogg lecturer and teaches a graduate-level course on medical product commercialization. Katie holds a BA from the University of Vermont.

His experience comprises a broad range of clinical and therapeutic areas, including orthopedics, wound care, in vitro diagnostics, general surgery, and cardiovascular surgery. His experience includes work with cardiovascular stents, catheters, human tissue (dermis and bone), animal tissue, drug-device combination products, electromechanical and wound care devices, in vitro diagnostic analyzers, assays, reagents, electrodes, and accessories.

Mr. Young’s extensive face-to-face experience with the FDA includes hundreds of submissions for Class II and Class III devices. He has developed quality systems from the ground up and has led inspections and audits with FDA, Canada, Europe, Australia and state health organizations. His international experience includes obtaining the first approval for a new technology category in Japan and a first foreign approval for a new technology category in China.

Mr. Young’s has published articles in Regulatory Affairs Focus and authored a chapter in the 2016 Global Medical Device Regulatory Strategy Textbook.  He has led successful efforts to bring new and highly differentiated products to the US, Canada, Europe, Japan, India, China, Japan and Brazil.

He received his Bachelor of Science in Medical Technology from the University of Iowa and his Master’s in Business Administration from Duke University’s Fuqua School of Business.